Skip to content
Clinical Trials – home
Not yet recruitingRare disease

Study of Encaleret Hemisulfate Hemihydrate for Efficacy, Safety and Tolerability in Adults with Chronic Hypoparathyroidism

Verified siteInvestigational
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

What is this trial about?

A plain-language summary of the goals, design and what participants do

The study focuses on individuals with Chronic Hypoparathyroidism, a rare condition in which the parathyroid glands do not make enough hormone, resulting in low calcium levels in the blood. The medication being tested is Encaleret, an oral tablet taken by mouth, and it is compared with a matching placebo. The aim is to determine whether the drug can increase the amount of calcium in the blood and reduce the amount of calcium that is excreted in the urine over a 24‑hour period.

The purpose of the study is to show the effectiveness of the drug in improving calcium balance. Participants will be randomly assigned to receive either the active tablet or the placebo for several months, with regular visits to monitor blood calcium, urine calcium, and any side effects. After the initial blinded phase, participants may enter an open‑label extension where everyone receives the active medication, allowing longer‑term safety and tolerability information to be gathered.

The research process

The trial runs in 6 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Randomization and Baseline Evaluation

    After joining the study you will be assigned randomly to receive either the active drug or a matching placebo. This process is called randomization and ensures that the groups are comparable.

    At the same visit a set of baseline measurements will be taken, including blood calcium level, 24‑hour urinary calcium excretion, and information about any calcium or vitamin D supplements you are currently using.

  2. Step 2

    Start Taking Study Medication

    You will begin taking the study medication orally as a film‑coated tablet. The tablet is taken once daily, with the dose specified by the study protocol.

    If you are assigned to the placebo group, you will take a tablet that looks identical but contains no active substance.

  3. Step 3

    Regular Study Visits and Laboratory Tests

    During the first 24 weeks you will attend study visits approximately every four weeks. At each visit blood will be drawn to measure calcium (referred to as cCa) and a 24‑hour urine collection will be performed to assess urinary calcium (referred to as UCa).

    The study staff will also record any changes in your calcium supplements, active vitamin D dose, and any adverse effects you may experience.

  4. Step 4

    End of Double‑Blind Period (Week 24)

    At week 24 the double‑blind phase ends. Your blood calcium, urinary calcium, and use of calcium or vitamin D supplements will be compared with the baseline values to determine whether a biochemical response has been achieved.

    If you meet the primary response criteria, additional analyses will be performed to evaluate reductions in supplement doses and independence from conventional therapy.

  5. Step 5

    Open‑Label Extension Begins

    After the double‑blind period you may enter an open‑label extension in which all participants receive the active drug, encaleret, for an extended period.

    The same daily oral tablet will be taken, and the dosage may be adjusted by the study team based on your laboratory results.

  6. Step 6

    Ongoing Monitoring During Extension

    During the extension you will continue to have regular visits for blood and urine testing, safety assessments, and review of supplement use.

    The study will track long‑term efficacy, safety, and tolerability of encaleret over the extended treatment period.

Who can join the trial?

7 criteria

  • Be at least 16 years old (or at least 18 years old if you live in the European Union) when you sign the study form, and have a confirmed diagnosis of chronic hypoparathyroidism for at least 26 weeks; this means you have had low blood calcium (hypocalcemia) together with abnormally low levels of the hormone parathyroid hormone (PTH).
  • If your condition is not caused by surgery, you must provide a copy of a previous genetic test showing that you do not have harmful changes (called pathogenic variants) in the CASR or GNA11 genes, or you must agree to have this genetic testing done for the study.
  • You need to have been taking a steady amount of calcium and active vitamin D supplements for at least 6 weeks before screening. The required amounts are: calcitriol (or alfacalcidol) at least 0.5 µg per day, and, if you are not in Japan, at least 800 mg of elemental calcium per day (calcium from tablets such as calcium citrate or calcium carbonate). If you are in Japan, you do not need a set calcium amount before screening, but you must be willing to take calcium supplements during the study if needed.
  • You must have blood calcium and 24‑hour urine calcium levels that meet the study’s specific ranges during the screening visit.
  • Your blood level of vitamin D (measured as 25‑hydroxy vitamin D) must be between 20 and 80 ng/mL.
  • Your blood magnesium level must be within the normal laboratory range.
  • You must be able to sign an informed consent form (or assent if you are a minor) and agree to follow the study’s rules and procedures.

Who cannot join the trial?

4 criteria

  • Having a genetic form of low calcium called autosomal dominant hypocalcemia type 1 or type 2, which is caused by specific changes (called activating variants) in the CASR or GNA11 genes.
  • Having had a hypocalcemic seizure (a seizure triggered by low calcium levels) within the three months before the screening visit.
  • Having any of the following serious health problems in the past five years: most types of cancer (except thyroid cancer, basal cell skin cancer, or squamous cell skin cancer), bone‑related cancers (skeletal malignancies), cancer that has spread to bone (bone metastases), radiation treatment to the skeleton (irradiation), chemotherapy that uses alkylating agents, Paget disease (a bone disorder), fibrous dysplasia (abnormal bone growth), chronic osteomyelitis (long‑term bone infection), bone infarcts (areas of dead bone tissue), benign bone tumors that required removal and bone grafting, retinoblastoma (eye cancer in children), or a genetic condition called Li‑Fraumeni syndrome. Prior whole‑body radioactive iodine treatment for thyroid cancer does not exclude you.
  • Having any other disease, condition, or problem (for example, drug or alcohol dependence) that the doctor believes could make the study unsafe, could make it hard for you to follow the treatment plan, or could cause you to leave the study early.
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not yet recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

Encaleret is an oral, film‑coated tablet that contains the active ingredient encaleret hemisulfate hemihydrate. It is being studied as a treatment for chronic hypoparathyroidism, a condition where the body does not produce enough parathyroid hormone, leading to low calcium levels. In the trial, participants take the tablet to see if it can raise the amount of calcium in the blood and reduce the amount of calcium lost in the urine. The study will check how well the medicine works and whether it is safe and tolerable for patients.

What is already known about the treatment

Encaleret tablets (GEN2) - Encaleret is taken by mouth as a film‑coated tablet that dissolves in the stomach. It is an approved orphan drug used for chronic hypoparathyroidism, a rare condition where the body lacks enough parathyroid hormone to keep calcium levels normal. The medicine works by providing a synthetic form of parathyroid hormone that binds to receptors on bone and kidney cells, helping the body raise blood calcium and reduce calcium loss in urine. It belongs to the class of hormone replacement therapies.

Investigated diseases

  • Hypoparathyroidism

    A condition in which the parathyroid glands produce insufficient amounts of parathyroid hormone, leading to low levels of calcium in the blood. Without enough hormone, calcium is not released from bones or reabsorbed by the kidneys, causing a gradual decline in blood calcium. Symptoms may develop slowly as calcium levels fall, affecting muscle function and nerve signaling. Over time, the body attempts to compensate, but calcium remains below normal. The low calcium state can persist unless the underlying hormone deficiency changes.

  • Chronic hypoparathyroidism

    A long‑lasting form of hypoparathyroidism that continues for months or years after the initial hormone deficiency appears. The persistent lack of parathyroid hormone keeps blood calcium consistently low, and the body does not recover on its own. Calcium balance remains abnormal, leading to ongoing adjustments in bone and kidney handling of minerals. The condition typically follows an initial acute phase and then stabilizes at a reduced calcium level. It remains present until an effective intervention alters hormone production or calcium regulation.

Trial detailsLast updated 18 Nov 2026
Age18+ yearsPhasePhase IIITrial ID2026-526140-13-00Protocol codeCLTX-305-304Estimated enrolment100 patientsSponsorCalcilytix Therapeutics Inc.

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.